AFMD - Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer | Benzinga
MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract with a comparison of NK cell redirected by the Company's innate cell engagers (ICE®) versus CAR-NK cells has been accepted for poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 1-5, 2023 in San Diego, California.
Details of the poster presentation are as follows:
Title: Redirecting NK cell cytotoxicity by Innate Cell Engagers: A differentiated and innovative approach compared to CAR-NK cells
Presenting Author: Sonya Ioana Ciulean
Abstract Number: 329
Poster Presentation Time: Friday, Nov. 3, 2023, 12:00 – 1:30 p.m. and 5:10 – 6:40 p.m.
Location: Exhibit Halls A and B1 – San Diego Convention Center
More details about the SITC conference are available online at Home - SITC 2023 (sitcancer.org)
About Affimed N.V.
Affimed (NASDAQ:AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company's proprietary ROCK® ...